Datapoint: Court Ruling Shores Up Eliquis Exclusivity Until 2028

The U.S. Court of Appeals for the Federal Circuit on Sept. 3 upheld a lower court decision that maintains Bristol Myers Squibb and Pfizer’s U.S. exclusivity for their blockbuster heart drug Eliquis until 2028. The ruling is still subject to appeal, however. Eliquis is one of the top-selling drugs in the U.S., and currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. 82.3% of all covered lives have unrestricted preferred access to Eliquis.

SOURCE: MMIT Analytics, as of 9/8/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today